2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
20
Prostatic Neoplasms
7
Triple Negative Breast Neoplasms
6
Ovarian Neoplasms
4
Neoplasm Metastasis
4
Melanoma
3
Lymphoma
3
Lung Neoplasms
3
Hematologic Neoplasms
3
Endometrial Neoplasms
3
Uterine Cervical Neoplasms
2
Recurrence
2
Neoplasms
2
Multiple Myeloma
2
Locally Advanced (Inoperable) or Metastatic Breast Cancer
2
Leukemia
2
Healthy Participants
2
Disease Progression
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumour
1
Rectal Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Interventions
Gels
2
Fulvestrant
2
Doxycycline
2
Dapsone
2
ruxolitinib
1
dexpanthenol
1
ceterizine hydrochloride
1
capivasertib
1
benralizumab
1
Triamcinolone Acetonide
1
Tetracycline
1
Sirolimus
1
Provitamins
1
Prednisone
1
Panitumumab
1
Minocycline
1
Loperamide
1
Irinotecan
1
Interviews as Topic
1
IFL protocol
1
Hydrocortisone
1
HIV Testing
1
Fibroblast Growth Factor 7
1
Erlotinib Hydrochloride
1
Clindamycin
1
Cetuximab
1
Anti-Bacterial Agents
1
Alpelisib
1
Acitretin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Exanthema
×
capivasertib
×
Clear all
NCT07426822
2026-02-24
SAFE-CAP
Yale University
Phase 2
Not yet recruiting
108 enrolled